The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Open accessAbstract
Antigen presentation by host dendritic cells (DC) is critical for the initiation of adaptive immune responses. We have previously demonstrated in immunogenic murine tumor models that bone marrow (BM)-derived DC pulsed ex vivo with synthetic tumor-associated peptides, naturally expressed by tumor cells, serve as effective antitumor vaccines, protecting animals against an otherwise lethal tumor challenge (Mayordomo, J.I., T. Zorina, W.J. Storkus, C. Celluzzi, L.D. Falo, C.J. Melief, T. Ildstad, W.M. Kast, A.B. DeLeo, and M.T. Lotze. 1995. Nature Med. 1:1297-1302). However, T cell-defined epitopes have not been identified for most human cancers. To explore the utility of this approach in the treatment of tumors expressing as yet uncharacterized epitopes, syngeneic granulocyte/macrophage colony-stimulating factor-stimulated and BM-derived DC, pulsed with unfractionated acid-eluted tumor peptides (Storkus, W.J., H.J. Zeh III, R.D. Salter, and M.T. Lotze. 1993. J. Immunother. 14:94-103) were used to treat mice bearing spontaneous, established tumors. The adoptive transfer of 5 x 10(5) tumor peptide-pulsed DC dramatically suppressed the growth of weakly immunogenic tumors in day 4 to day 8 established MCA205 (H-2b) and TS/A (H-2d) tumor models, when applied in three biweekly intravenous injections. Using the immunogenic C3 (H-2b) tumor model in B6 mice, tumor peptide-pulsed DC therapy resulted in the erradication of established d14 tumors and long-term survival in 100% of treated animals. The DC-driven antitumor immune response was primarily cell mediated since the transfer of spleen cells, but not sera, from immunized mice efficiently protected sublethally irradiated naive mice against a subsequent tumor challenge. Furthermore, depletion of either CD4+ or CD8+ T cells from tumor-bearing mice before therapy totally suppressed the therapeutic efficacy of DC pulsed with tumor-derived peptides. Costimulation of the host cell-mediated antitumor immunity was critical since inoculation of the chimeric fusion protein CTLA4-Ig virtually abrogated the therapeutic effects of peptide-pulsed DC in vivo. The analysis of the cytokine pattern in the draining lymph nodes and spleens of tumor-bearing mice immunized with DC pulsed with tumor-eluted peptides revealed a marked upregulation of interleukin (IL) 4 and interferon (IFN) gamma production, as compared with mice immunized with DC alone or DC pulsed with irrelevant peptides. DC-induced antitumor effects were completely blocked by coadministration of neutralizing monoclonal antibody directed against T helper cell 1-associated cytokines (such as IL-12, tumor necrosis factor alpha, IFN-gamma), and eventually, but not initially, blocked by anti-mIL-4 mAb. Based on these results, we believe that DC pulsed with acid-eluted peptides derived from autologous tumors represents a novel approach to the treatment of established, weakly immunogenic tumors, and serves as a basis for designing clinical trials in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
Steinman, R. M., & Cohn, Z. A. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.137.5.1142 · Cited by 2,424
Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., & Trinchieri, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.827 · Cited by 1,953
Proliferating dendritic cell progenitors in human blood.
Romani, N., Gruner, S., Brang, D., Kämpgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., & Schuler, G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.83 · Cited by 1,840
Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells.
Macatonia, S. E., Hosken, N. A., Litton, M., Vieira, P., Hsieh, C. S., Culpepper, J. A., Wysocka, M., Trinchieri, G., Murphy, K. M., & O'Garra, A. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.10.5071 · Cited by 1,524
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro.
Schuler, G., & Steinman, R. M. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.3.526 · Cited by 1,123
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Self-citationChen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050
Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., & Slingluff, C. L. (1994) · Science · doi:10.1126/science.7513441 · Cited by 824
Sarmiento, M., Glasebrook, A. L., & Fitch, F. W. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.6.2665 · Cited by 802
Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule
Linsley, P. S., Wallace, P. M., Johnson, J., Gibson, M. G., Greene, J. L., Ledbetter, J. A., Singh, C., & Tepper, M. A. (1992) · Science · doi:10.1126/science.1496399 · Cited by 790
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., & Falo, L. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.283 · Cited by 717
Self-citationWysocka, M., Kubin, M., Vieira, L. Q., Ozmen, L., Garotta, G., Scott, P., & Trinchieri, G. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250307 · Cited by 467
Identification of proliferating dendritic cell precursors in mouse blood.
Inaba, K., Steinman, R. M., Pack, M. W., Aya, H., Inaba, M., Sudo, T., Wolpe, S., & Schuler, G. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.5.1157 · Cited by 446
Activated T cells induce interleukin‐12 production by monocytes via CD40‐CD40 ligand interaction
Shu, U., Kiniwa, M., Wu, C. Y., Maliszewski, C., Vezzio, N., Hakimi, J., Gately, M., & Delespesse, G. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250442 · Cited by 414
Sheehan, K. C. F., Ruddle, N. H., & Schreiber, R. D. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.11.3884 · Cited by 379
Berendt, M. J., & North, R. J. (1980) · The Journal of experimental medicine · doi:10.1084/jem.151.1.69 · Cited by 369
Paracrine Cytokine Adjuvants in Cancer Immunotherapy
Pardoll, D. M. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.399 · Cited by 369
Wilde, D. B., Marrack, P., Kappler, J., Dialynas, D. P., & Fitch, F. W. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.5.2178 · Cited by 365
Porgador, A., & Gilboa, E. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.255 · Cited by 362
Finkelman, F. D., Katona, I. M., Urban, J. F., Snapper, C. M., Ohara, J., & Paul, W. E. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.24.9675 · Cited by 349
Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Bazin, H., Tielemans, F., Leo, O., Urbain, J., & Moser, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240317 · Cited by 291
Schmitt, E., Hoehn, P., Huels, C., Goedert, S., Palm, N., Rüde, E., & Germann, T. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240403 · Cited by 287
Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells
Tepper, R. I., & Mulé, J. J. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.2-153 · Cited by 254
Grabbe, S., Beissert, S., Schwarz, T., & Granstein, R. D. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80125-1 · Cited by 250
Lu, L., Woo, J., Rao, A. S., Li, Y., Watkins, S. C., Qian, S., Starzl, T. E., Demetris, A. J., & Thomson, A. W. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.6.1823 · Cited by 241
TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma
Nanni, P., De Giovanni, C., Lollini, P.-L., Nicoletti, G., & Prodi, G. (1983) · Clinical & Experimental Metastasis · doi:10.1007/bf00121199 · Cited by 226
Antigen processing in vivo and the elicitation of primary CTL responses.
Restifo, N. P., Bacík, I., Irvine, K. R., Yewdell, J. W., McCabe, B. J., Anderson, R. W., Eisenlohr, L. C., Rosenberg, S. A., & Bennink, J. R. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.9.4414 · Cited by 217
Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
Noguchi, Y., Richards, E. C., Chen, Y. T., & Old, L. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2219 · Cited by 212
Tumor antigen presentation by murine epidermal cells
Grabbe, S., Bruvers, S., Gallo, R. L., Knisely, T. L., Nazareno, R., & Granstein, R. D. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.10.3656 · Cited by 200
Interleukin‐12 regulates the proliferation of Th1, but not Th2 or Th0, clones
Kennedy, M. K., Picha, K. S., Shanebeck, K. D., Anderson, D. M., & Grabstein, K. H. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241002 · Cited by 117
Gajewski, T. F., Renauld, J., Pel, A. V., & Boon, T. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.11.5637 · Cited by 104
Streilein, J. W., Grammer, S. F., Yoshikawa, T., Demidem, A., & Vermeer, M. (1990) · Immunological Reviews · doi:10.1111/j.1600-065x.1990.tb00572.x · Cited by 101
Mouse tumor rejection antigens P815A and P815B : Two epitopes carried by a single peptide
Lethé, B., den Eynde, B. J. V., Pel, A. V., Corradin, G., & Boon, T. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220916 · Cited by 99
Cohen, P., Cohen, P. A., Rosenberg, S. A., Mulé, J. J., & Katz, S. I. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240206 · Cited by 98
Cited by
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D., Ricciardi-Castagnoli, P., Raposo, G., & Amigorena, S. (1998) · Nature Medicine · doi:10.1038/nm0598-594 · Cited by 2,266
Self-citationGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Self-citation
Metadata
- Authors
- Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., & Storkus, W. J.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1996-01-01
- Volume
- 183
- Issue
- 1
- Pages
- 87-97
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2099458553
- Cited by
- 828
- References
- 37
- FWCI
- 33.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.